Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes
Get Live Data
23.00    0.00 (0.00%)
Bid:
22.00
Ask:
24.00
Spread: 2.00 (9.091%)
Market Cap: £31.87m
SAR Live PriceLast checked at - London Stock Exchange

Intraday Sareum Share Chart

Rule 8 - Sareum Holdings plc

7 Mar 2005 12:01

Sareum Holdings PLC07 March 2005 Date of Disclosure 7 March 2005 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) AND 8.3 OF THE CITY CODE ON TAKEOVERSAND MERGERS Date of dealing 4 March 2005 Dealing in SAREUM HOLDINGS PLC (1) Class of securities (eg ordinary shares) Ordinary Shares (2) Amount sold Price per unit Peter Hoskins 250,000 2.75p (3) Resultant total of the same class owned or controlled (and percentage ofclass) Resultant holding for party named above: 7,700,050 (2.21%) (4) Party making disclosure Peter Hoskins (5) EITHER (a) Name of vendor (Note 1) Peter Hoskins OR (b) If dealing fordiscretionary client(s), name of fund management organisation (6) Reason for disclosure (Note 2) (a) associate of (i) offeror (Note 3) No (ii) offeree company NoSpecify which category or categories of associate (1-8 overleaf)If category (8), explain. (b) Rule 8.3 (ie disclosure because of ownership or control of 1% or more of theclass of relevant securities dealt in) YES Signed, for and on behalf of the party named in (4) above N/A (Also print name of signatory) Peter Hoskins Telephone and extension number 01799 530084______________________________________ Note 1. Specify owner, not nominee or vehicle company. If relevant, alsoidentify controller of owner, eg where an owner normally acts on instructions ofa controller. Note 2. Disclosure might be made for more than one reason; if so, state allreasons. Note 3. Specify which offeror if there is more than one. Note 4. When an arrangement exists with any offeror, with the offeree companyor with an associate of any offeror or of the offeree company in relation torelevantsecurities, details of such arrangement must be disclosed, as required by Note 6on Rule 8. Note 5. It may be necessary, particularly when disclosing derivativetransactions, to append a sheet to this disclosure form so that all relevantinformation can be given. Note 6. In the case of an average price bargain, each underlying trade should bedisclosed. Note 7. The resultant total percentage holding of the class of relevant securityis to be calculated by reference to the percentage held and in issue outsidetreasury. For full details of disclosure requirements, see Rule 8 of the Code. If indoubt, contact the Panel on Takeovers and Mergers, Monitoring Section, Tel. No:020 7638 0129. E-mail: monitoring@disclosure.org.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Jun 20269:40 amRNSPublication of Phase 1 data on SDC-1801 in BJCP
1st May 20267:00 amRNSExercise of Warrants
12th Mar 20267:00 amRNSHalf-Year Report for Six Months Ended 31 Dec 2025
12th Mar 20267:00 amRNSHalf-Year Report for Six Months Ended 31 Dec 2025
3rd Mar 20267:00 amRNSNotice of Results and Investor Presentation
17th Feb 20267:00 amRNSRestart of Phase 2-enabling toxicology programme
23rd Jan 20264:36 pmRNSForm 8.3 - Oxford Biomedica plc
9th Dec 20254:25 pmRNSResults of AGM
9th Dec 20257:00 amRNSAnnual General Meeting Statement
17th Nov 20257:00 amRNSNotice of AGM, Annual Report and Accounts
30th Oct 20257:00 amRNSAppointment of Joint Corporate Broker
23rd Oct 20257:00 amRNSPreliminary Results for Year Ended 30 June 2025
10th Oct 20257:00 amRNSUpdate on toxicology study for SDC-1801
7th Oct 20257:00 amRNSNotice of Results and Investor Presentation
26th Sep 20253:12 pmRNSExercise of Warrants
18th Sep 202512:59 pmRNSExercise of Warrants
26th Aug 20257:00 amRNSExercise of Warrants
20th Aug 202510:01 amRNSExercise of Warrants
12th Aug 20257:00 amRNSSareum Collaboration with Receptor.AI
9th Jul 20257:00 amRNSExercise of Warrants
4th Jul 20257:00 amRNSAppointment of Sole Broker
29th May 20257:00 amRNSInitiation of Toxicology Studies for SDC-1801
28th Apr 20257:00 amRNSUpdate on TYK2/JAK1 and SRA737 Programmes
24th Apr 20257:00 amRNSExercise of Warrants
27th Mar 20257:00 amRNSDirector’s Dealing
25th Mar 20257:00 amRNSSareum Half-Year Report
20th Mar 20257:00 amRNSNotice of HY Results and Investor Presentation
13th Mar 20257:15 amRNSInstitutional Equity Fundraise
13th Mar 20257:08 amRNSSareum Acquires Licence for SRA737
31st Dec 20247:00 amRNSUpdate on SRA737
19th Dec 20244:07 pmRNSResults of AGM
19th Dec 20247:00 amRNSAGM Statement
18th Dec 20247:00 amRNSAppointment of Joint Broker
17th Dec 20249:14 amRNSHolding(s) in Company
16th Dec 20247:00 amRNSAward of Share Options
27th Nov 20249:38 amRNSNotice of AGM, Annual Report and Accounts
29th Oct 20247:00 amRNSFinal Results for the Year Ended 30 June 2024
23rd Oct 20247:00 amRNSNotice of Final Results and Investor Presentation
21st Oct 20247:00 amRNSFurther Subscription to raise £1,000,000
11th Oct 20247:00 amRNSSubscription to raise £2,364,000
16th Sep 20247:00 amRNSPatent Allowance in China
2nd Sep 20247:00 amRNSUS patent allowance
10th Jul 20247:00 amRNSManagement Changes
1st Jul 20247:00 amRNSPositive Data from SDC-1801 Phase 1 Clinical Trial
30th May 20247:00 amRNSAppointment of Sole Broker
7th May 20242:10 pmRNSExercise of Warrants
23rd Apr 20247:00 amRNSFinal Issue of RiverFort Subscription Shares
19th Apr 202411:35 amRNSIssue of RiverFort Subscription Shares
15th Apr 20243:28 pmRNSIssue of RiverFort Subscription Shares
9th Apr 20244:00 pmRNSIssue of RiverFort Subscription Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.